MoA qu in GCA: Is one JAKi better? lab in tofa proof-of-concept in bari clinical trial in upa @MdWarrington: unclear if any diff clinically GM-CSF vs IL-17? Maria Cid: lots of redundancy in immune system blocking one pathway, escalation of another? we will see #ACR22 @RheumNow

Combined pulmonary HTN and ILD seen in 7% in large scleroderma database. Unsurprisingly, survival worse then PAH/ILD alone. HAQ also worse in this group. @RheumNow @earlyARA #ACR22 ABST1058 https://t.co/Jr58wVLC31 https://t.co/UCjKuJB1ev

• Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertensi…

Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97

• Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1…

Great scientific talk by John Stone, IgG4-RD should be a considered a variable-vessel disease, much like Behcet's and Cogan's syndrome I had not viewed it from that perspective; adding it to the list! Series of patietns w/coronary involvement esp interesting #ACR22 @RheumNow https://t.co/JUayLOTnSB

Slow pruning of Pulmonary arteries occurs way before we detect #PAH pulmonary hypertension in #scleroderma #SSc 13S114 lecture by Fred Wigley. Screen but need data re earlier Rx before Dx of PAH. May be assoc w anticentrome and +++ telangiectasia ⁦@RheumNow⁩ #ACR22 https://t.co/AgnIMYFKjB

#ACR22 Abstr#1464 Press Release #lupus. Should we worry of pts without nephritis & low grade proteinuria UPCR >0.2 & <0.5? A cohort study showed 50% progressed to =>0.5 at 2 yrs & 11% renal biopsy +ve. Important to monitor UPCR. Need biomarkers for this At-Risk @RheumNow #ACRBest https://t.co/eOODUynvP4

PCP docs managing AS? Abstract #0078 🧑‍⚕️ Assessed differences in management between PCP and rheumatologists 💉RHU prescribed more biologics 💊PCP prescribed more opiate and non-opiate pain medications 💊PCP did not often prescribe csDMARDs or biologics #ACR22 @RheumNow

1918 influenza brought us proper design of vaccine trials as well as discovery of the influenza virus @RheumNow #ACR22 @HRheuminations https://t.co/RlNXSWMWBz

Please see my short review on new data and progress of BAFF/APRIL inhibition in #lupus #SLE presented at #ACR22 @RheumNow https://t.co/pqxdAcMH5e https://t.co/9IIrxVZvGe

• Dual target blockade may be better than one in SLE | RheumNow

Ab0575 #ACR22 MI/CVA in Osteoporosis Pts on DEN/ ZOL, L Spangler DEN pts more likely CKD, adjusted analysis At 36 mos, risk for Den vs Zol in 2 database claims: - MI: 0.97, 1.22 (0.8-1.7) - CVA: 0.9 (0.6-1.2), 1.0 No incr. risk identified with Den vs Zol in MI or CVA @RheumNow https://t.co/hgyG1ZmFLT

Other potential mechanisms for survival selection against the plague via MHC presentation to CD8 T cells. May be associated with SpA/HLA B27 @RheumNow @HRheuminations #ACR22 #rheuminations https://t.co/Rv117B4IYp

Dr. Wigley describes the edematous phase of early #scleroderma: ☝️ Friction rubs are a sign of active disease and assoc. with poor outcomes #ACR22 @RheumNow @rheumarhyme https://t.co/ooXYp1wXzu

Did you know that the first virus, the tobacco mosaic virus, was described in 1892? @AdamJBrownMD gave a fascinating lecture today regarding that included the history of viruses. #ACR22 @RheumNow

Ab0577 #ACR22 Sao Paulo Aging & Health (SPAH) Radius 1/3 BMD enhance fx risk estimates when combined w/ spine (RR 1.4, p=0.03) For radius+hip or radius+spine/hip, radius DEXA is non-significant - only hip predicted fx Use radius BMD when hip unattainable- THA/severe OA @Rheumnow